Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO Biomanufacturing Training Hub Plan Offers Korea Chance On World Stage

Adds To Vaccine Ambitions

Executive Summary

South Korea welcomes WHO decision to designate the country as a global biomanufacturing training hub, citing various opportunities this could provide in fulfilling its goal of becoming a similar center of worldwide expertise in vaccines.

You may also be interested in...



Need For Skilled Workforce A Key Issue In Countries Using mRNA Tech Transfer

The World Health Organization is ramping up its efforts to provide lower-income countries with the ability to produce their own biological products, such as vaccines and monoclonal antibodies. A new biomanufacturing training facility is in the works, and more recipients of mRNA technology transfer for vaccine production are being chosen.

Korea Should Pursue Two-Pronged Strategy In Global Vaccine Hub Bid

South Korea is making a strategic push to strengthen its vaccine capabilities, with a focus on COVID-19 and future pandemics and the aim of becoming a global development hub. But one expert told a recent meeting that these goals should not overshadow the government’s original aim of becoming self-sufficient for the national immunization program.

Coronavirus Notebook: South Africa To Build mRNA Vaccine Tech Transfer Hub, EMA OKs More Comirnaty Production Capacity

MSF is pressuring Moderna and Pfizer/BioNTech to share their vaccine know-how with manufacturers in developing countries, and companies have just a few days to answer the European Commission's questions about COVID-19 therapies they have in development.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel